2-氨基-5-甲氧基苯甲酸甲酯 | 2475-80-1

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-5-甲氧基苯甲酸甲酯
• 中文别名: 甲基2-氨基-5-甲氧基苯甲酸酯
• 英文名称: methyl 2-amino-5-methoxybenzoate
• 英文别名: methyl 5-(methoxy)-2-aminobenzoate；methyl 5-methoxyanthranilate；2-amino-5-methoxybenzoic acid,methyl ester
• CAS: 2475-80-1
• 化学式: C₉H₁₁NO₃
• mdl: MFCD09038482
• 分子量: 181.191
• InChiKey: MOVBJUGHBJJKOW-UHFFFAOYSA-N

物化性质

• 熔点：
  37-38℃
• 沸点：
  298.8±20.0 °C(Predicted)
• 密度：
  1.179±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2922509090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  | 室温 |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Methyl 2-amino-5-methoxybenzoate
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Methyl 2-amino-5-methoxybenzoate
Ingredient name:
CAS number: 2475-80-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H11NO3
Molecular weight: 181.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-5-甲氧基苯甲酸甲酯 在 吡啶 、 二异丁基氢化铝 作用下， 生成 N-(2-(hydroxymethyl)-4-methoxyphenyl)-4-methylbenzenesulfonamide
  参考文献：
  名称：

  Synthesis of substituted 1,2-dihydroquinolines and quinolines using ene–ene metathesis and ene–enol ether metathesis

  摘要：

  We describe a novel and convenient method for quinoline synthesis using ring-closing olefin metathesis (RCM), ene-ene metathesis, and ene-enol ether metathesis. We also report the first example of enol silyl ether-ene metathesis to produce cyclic enol silyl ether. Using this method, versatile substituted quinoline derivatives were readily prepared in excellent yield from anthranilic acid derivatives. C 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)01714-2
• 作为产物：
  描述：

  5-甲氧基-2-硝基苯甲酸 在 tin(II) chloride dihdyrate 、 potassium carbonate 作用下， 以 甲醇 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 2-氨基-5-甲氧基苯甲酸甲酯
  参考文献：
  名称：

  可逆单酰基甘油脂肪酶（MAGL）抑制剂的第二代苯甲酰基哌啶衍生物的设计，合成和生物学评估

  摘要：

  内源性大麻素系统的一种有趣酶是单酰基甘油脂肪酶（MAGL）。该酶可代谢内源性大麻素2-花生四烯酰基甘油（2-AG），由于它参与了一些生理和病理过程，例如癌症进展，因此引起了极大的兴趣。实验证据突显了与体内不可逆MAGL抑制剂的使用相关的一些缺点因此，关于可逆抑制剂的研究领域正在迅速发展。在本手稿中，基于苯甲酰基哌啶的MAGL抑制剂的种类进一步扩大和优化。酶促测定法鉴定出了一些在低纳摩尔范围内的化合物，分子动力学模拟预测了最好的化合物之一与酶的解离路线，从而证实了所观察到的构效关系。生物学评估，包括在完整的U937细胞中进行测定以及在小鼠脑膜中进行基于竞争活性的蛋白质谱分析实验，证实了所选化合物对MAGL与内源性大麻素系统其他成分的选择性。在一组癌细胞系中的抗增殖能力凸显了它们作为潜在抗癌药的潜力。

  DOI：

  10.1016/j.ejmech.2020.112857

文献信息

• Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma
  作者：Xuewu Liang、Chenxia Sun、Chunpu Li、Haolan Yu、Xiaohui Wei、Xuyi Liu、Wei Bao、Yuqiang Shi、Xiaochen Sun、Mirzadavlat Khamrakulov、Chenghua Yang、Hong Liu

  DOI：10.1021/acs.jmedchem.1c00466

  日期：2021.7.8

  lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors is of great value and significance in the treatment of neoplastic disorders and inflammatory and autoimmune diseases. However, there is a lack of effective MALT1 inhibitors in clinic. Herein, a novel class of potent 5-oxo-1-thioxo-4,5-dihydro-1H-thiazolo[3,4-a]quinazoline-based MALT1 inhibitors and their covalent derivatives were first identified

  黏膜相关淋巴组织淋巴瘤易位蛋白 1 (MALT1) 抑制剂的开发在肿瘤性疾病、炎症和自身免疫性疾病的治疗中具有重要价值和意义。然而，临床上缺乏有效的MALT1抑制剂。在此，首次通过高通量鉴定和设计了一类新型有效的 5-oxo-1-thioxo-4,5-dihydro-1 H - thiazolo[3,4- a ]quinazoline 抑制剂及其共价衍生物。筛选。我们证明了化合物15c、15e和20c有效抑制 MALT1 蛋白酶并对活化的 B 细胞样弥漫性大 B 细胞淋巴瘤具有低个位数微摩尔效力显示出选择性细胞毒性。此外，化合物20c以剂量依赖性方式特异性抑制 MALT1 依赖性 TMD8 细胞中的 NF-κB 信号传导并诱导细胞凋亡。更重要的是，20c在 TMD8 异种移植肿瘤模型中显示出良好的药代动力学特性和抗肿瘤功效，且无显着毒性。总的来说，这项研究为 MALT1 抑制剂的进一步结构
• An efficient one-pot synthesis of 2-aminobenzothiazoles from substituted anilines using benzyltrimethylammonium dichloroiodate and ammonium thiocyanate in DMSO:H2O
  作者：Reuben Dass、Matt A. Peterson

  DOI：10.1016/j.tetlet.2021.153388

  日期：2021.10

  and ammonium thiocyanate (1.0 equiv) in DMSO:H2O (9:1) at 70 °C gave the corresponding 2-aminobenzothiazoles in excellent isolated yields (75–97%; ave. yield for all substrates = 90%). The reaction worked well for 2(4)-mono-, 2,4-di-, or 3,4,5-tri-substituted anilines, and a wide range of both electron donating groups (MeO, HO, CF3O, Me) and electron withdrawing groups (NO2, CN, CO2Et, CO2H, Cl, F)

  在 DMSO:H 2 O (9:1) 中，在 70 °C 下用苄基三甲基二氯碘酸铵（1.2 当量）和硫氰酸铵（1.0 当量）处理各种取代苯胺，得到相应的 2-氨基苯并噻唑，分离产率高（75-97 %；所有底物的平均产率 = 90%）。该反应适用于 2(4)-单-、2,4-二-或 3,4,5-三-取代的苯胺，以及范围广泛的两种给电子基团（MeO、H2O、CF 3 O、 Me）和吸电子基团（NO 2、CN、CO 2 Et、CO 2 H、Cl、F）耐受性良好。这种方法为其他方法提供了一种有用的替代方法，这些方法要么效率较低（需要 3-7 倍当量的试剂），要么使用剧毒和腐蚀性液体溴2作为氧化剂。
• SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF
  申请人：AJINOMOTO CO., LTD.

  公开号：US20150051395A1

  公开（公告）日：2015-02-19

  Provided are sulfonamide derivatives of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent α4 integrin-inhibitory action.

  提供的是具有特定化学结构的磺酰胺衍生物，在其末端有一个带有苯基或含杂原子的杂环基团作为取代基的磺酰胺基团，以及药用可接受的盐。这些化合物是具有卓越的α4整合素抑制作用的全新化合物。
• [EN] SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1<br/>[FR] AGONISTES À PETITES MOLÉCULES DE RÉCEPTEUR DE NEUROTENSINE 1
  申请人：SANFORD BURNHAM MED RES INST

  公开号：WO2014100501A1

  公开（公告）日：2014-06-26

  Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

  提供的是小分子神经降压素受体激动剂，包含这些化合物的组合物，以及使用这些化合物和包含这些化合物的组合物的方法。
• [EN] OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE<br/>[FR] OCTAHYDROCYCLOPENTAPYRROLES, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：UNIV COLUMBIA

  公开号：WO2014152018A1

  公开（公告）日：2014-09-25

  The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatement of diseases characterized by excessive lipofuscin accumulation in the retina.

  本发明提供了具有以下结构的八氢环戊吡咯化合物：(结构表示) 其中psi为不存在或存在，当存在时为键；R1、R2、R3、R4和R5各自独立为H、卤素、CF或C1-C4烷基；R6不存在或存在，当存在时为H、OH或卤素；A不存在或存在，当存在时为C(O)或C(O)NH；B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或(C1-C4烷基)-CO2H，其中当B为CO2H时，A存在且为C(O)；且当psi存在时，R6不存在，当psi不存在时，R6存在，或其药用可接受盐，用于治疗以视网膜过度脂褐素积聚为特征的疾病。